Ozempic Side Effects: What Is Common, What Is Rare and When to Call Your Doctor

Scroll through any group chat this year and someone is asking the same question in slightly different words: is the queasy feeling normal, and when does it stop being normal? Semaglutide, sold as Ozempic for type 2 diabetes and as Wegovy for weight management, has become one of the most talked-about medicines in the country, and its side effects have become dinner-table conversation.

The searches for Ozempic side effects spiked again in 2025 for concrete reasons: regulators in Europe concluded that a rare optic nerve condition can be linked to semaglutide, US regulators expanded the drug’s approved uses to kidney protection and a form of fatty liver disease, and viral posts about “stomach paralysis” kept circulating alongside the honest testimonials of people who felt sick for a month and then felt fine.

As of late 2025, the evidence is clearer than the noise suggests. What follows sorts it into three piles: common and usually manageable, uncommon and worth watching, and rare but serious enough to know by name.

What changed recently with Ozempic side effects

Three developments since early 2025 reshaped the conversation, and none of them was a new digestive complaint.

The first was about eyes. In June 2025, the European Medicines Agency’s safety committee reviewed a cluster of reports and observational studies and concluded that non-arteritic anterior ischemic optic neuropathy, or NAION, a sudden loss of blood flow to the optic nerve that can permanently dim vision in one eye, should be listed as a very rare side effect of semaglutide, meaning up to roughly 1 in 10,000 users. That is the first time a regulator moved the eye signal from “under review” to “listed.”

The second was about who takes the drug and why. In January 2025, the US Food and Drug Administration approved Ozempic to reduce the risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease, following the FLOW trial. In August 2025, Wegovy gained approval for metabolic dysfunction-associated steatohepatitis, the inflammatory form of fatty liver disease. More approved uses mean more people, including older adults and people with several chronic conditions, are now on the medicine, which changes how side effects show up in the real world.

The third was quieter but mattered for safety. The FDA declared the semaglutide shortage resolved in early 2025, which narrowed the legal room for compounded copies. Compounded versions had been tied to dosing-error reports, and the agency’s advice became blunter: the approved product, prescribed and monitored by a clinician, is the version whose side-effect profile is actually known.

Earlier label changes still shape today’s counseling. In September 2023 the FDA added ileus, a temporary shutdown of bowel movement, to the Ozempic label based on post-marketing reports. In late 2024 anesthesia societies and regulators highlighted rare cases of stomach contents being inhaled during sedation, because the drug slows gastric emptying. None of these are new molecules or new mechanisms; they are the same drug, watched by many more eyes.

How semaglutide works, and why the gut feels it first

Semaglutide imitates GLP-1, short for glucagon-like peptide-1, a hormone your small intestine releases after a meal. The natural hormone lasts a couple of minutes; the medicine is engineered to linger about a week, which is why it is a once-weekly injection.

GLP-1 does four things that matter for both benefit and side effects. It tells the pancreas to release insulin when blood sugar is high. It quiets glucagon, the hormone that raises blood sugar. It slows the rate at which the stomach empties into the intestine. And it acts on appetite centers in the brainstem and hypothalamus, so a normal portion feels like enough.

Look at that list and the side-effect pattern almost predicts itself. Slow the stomach and food sits longer; that is nausea, fullness, belching and reflux. Slow the whole tract and stool moves less; that is constipation. Alter gut signaling and some people swing the other way; that is diarrhea. Reduce appetite sharply and some people simply forget to drink, which is where dehydration and kidney strain enter the picture. Even the gallbladder story connects here: rapid weight loss from any cause, diet included, is a known trigger for gallstones.

The Cleveland Clinic’s overview of GLP-1 agonists makes the same point in plainer words: the side effects are mostly the mechanism, felt too strongly. That framing is useful because it explains the timing. Effects on stomach emptying are strongest when the drug is first started and each time the dose is stepped up, and the stomach adapts over several weeks. Trial data bear this out: in the STEP 1 weight-management trial, nausea peaked during the dose-escalation months and declined steadily afterward, even as the drug level in the blood stayed high.

Understanding this does not make anyone feel less queasy on week two. It does help separate an expected adjustment from a signal that something else is going on.

Which Ozempic side effects are most common?

Nausea sits at the top, and by a wide margin. In the SUSTAIN trials that underpin Ozempic’s diabetes approval, roughly 16 to 20 percent of people on the drug reported nausea, compared with about 6 percent on placebo. Diarrhea affected about 9 percent, vomiting 5 to 9 percent, abdominal pain 6 to 7 percent and constipation 3 to 5 percent. MedlinePlus lists the same cluster, along with heartburn, burping, gas and a smaller appetite, as the effects to expect.

Two things about these numbers deserve emphasis. First, they describe people who reported the symptom at least once over more than a year, not people who felt sick every day. Second, most episodes were rated mild or moderate. In the trials, only about 3 to 4 percent of participants stopped Ozempic because of gastrointestinal effects.

Beyond the gut, a handful of common effects are easy to miss. Fatigue during the first weeks is frequently reported, partly because people are eating far less. Headache appears in a minority. Injection-site redness or itching occurs in a small percentage and usually fades within a day or two. A modest rise in resting heart rate, on average 1 to 4 beats per minute, was measured in trials; most people never notice it, but it is one reason clinicians check pulse at follow-up.

Reflux deserves its own mention. When the stomach empties slowly, acid has more time to travel upward, and people with pre-existing heartburn sometimes find it worsens. Eating smaller meals and not lying down soon after eating are the standard, low-risk suggestions, and they come from the same clinics that prescribe the drug.

What about “sulfur burps,” the odd, eggy belching that fills online forums? It is not listed as a formal trial outcome, but it is a plausible consequence of food fermenting longer in a slow stomach. Common in anecdote, benign in mechanism, and worth mentioning to a clinician only if it comes with pain or vomiting.

Ozempic vs Wegovy side effects: the same molecule at different strengths

Ozempic and Wegovy contain the identical active ingredient, semaglutide. The difference is the approved use and the maximum strength: Wegovy is dosed higher for weight management, and the side-effect numbers rise accordingly. That single fact explains most of the confusion when people compare notes across the two brands.

The STEP 1 trial, published in the New England Journal of Medicine in 2021 and indexed on PubMed, followed nearly 2,000 adults for 68 weeks. It remains the clearest picture of Wegovy side effects at the full weight-management strength. The comparison below uses that trial alongside the pooled Ozempic diabetes trials.

Side effect	Ozempic (diabetes trials)	Wegovy (STEP 1)	Placebo (STEP 1)
Nausea	16–20%	44%	17%
Diarrhea	~9%	32%	16%
Vomiting	5–9%	25%	7%
Constipation	3–5%	24%	11%
Abdominal pain	6–7%	20%	10%
Stopped drug for GI reasons	~3–4%	4.5%	0.8%

Notice the placebo column. Seventeen percent of people taking a dummy injection reported nausea, and 11 percent reported constipation, partly because everyone in the trial was also following a reduced-calorie diet and exercise plan. The drug’s true added burden is the gap between the columns, not the raw number.

Notice, too, that despite nausea in nearly half of participants, fewer than one in twenty quit because of it. Most people found the symptoms tolerable, temporary, or both. Hair loss was reported by 3 percent on Wegovy versus 1 percent on placebo, and gallbladder-related events by 2.6 percent versus 1.2 percent, both discussed later.

Which strength a person should be on, and how quickly to move between strengths, is a clinical judgment. Slower stepping is a recognized way to reduce GI effects, and it is the prescriber’s call, made with the patient, based on how the previous weeks went.

Ozempic gallbladder problems: what the data actually show

The gallbladder is a small pouch under the liver that stores bile, the fluid that digests fat. Gallstones form when that bile thickens and crystallizes, and cholecystitis is the inflammation that follows when a stone blocks the outlet. Both are more common with rapid weight loss of any kind, and both show up in semaglutide trials.

The best single summary comes from a 2022 meta-analysis in JAMA Internal Medicine, indexed on PubMed, that pooled 76 randomized trials of GLP-1 receptor agonists covering more than 100,000 participants. People on these drugs had about a 37 percent higher relative risk of gallbladder or biliary disease than people on placebo or comparators. The absolute increase was small: roughly 27 additional events per 10,000 person-years. The risk was higher at the doses used for weight loss, with longer treatment, and when the drug was prescribed for weight rather than diabetes.

That fits STEP 1, where gallbladder-related disorders occurred in 2.6 percent of the Wegovy group and 1.2 percent of the placebo group, mostly gallstones. Because randomized trials are the highest tier of evidence and this finding is consistent across many of them, the ozempic gallbladder link is considered established rather than speculative. The Mayo Clinic and MedlinePlus both list gallbladder disease among the side effects that require contacting a doctor.

Why does it happen? Two mechanisms are likely working together. Weight loss itself changes bile composition and increases cholesterol saturation. GLP-1 may also reduce gallbladder contractions, so bile sits longer and stones have time to form. Whether the drug adds risk beyond the weight loss it produces is not fully settled.

The symptom to know is biliary colic: a steady, often severe pain in the upper right or middle abdomen, sometimes spreading to the right shoulder blade, typically an hour or two after a fatty meal, lasting from thirty minutes to several hours. Fever, yellowing of the skin or eyes, or pale stools alongside that pain point to a blockage or infection and call for same-day care.

Ozempic pancreatitis: rare, serious, and what it feels like

Pancreatitis is inflammation of the pancreas, the organ behind the stomach that makes insulin and digestive enzymes. It ranks among the most feared ozempic pancreatitis questions online, and the honest answer has two halves: the label warns about it, and the trials did not prove the drug causes it.

The warning exists because early GLP-1 drugs, more than a decade ago, generated case reports of acute pancreatitis, and because animal studies showed changes in pancreatic tissue. Every drug in the class now carries the caution. Semaglutide trials tracked pancreatitis carefully. In the pooled Ozempic diabetes trials, confirmed acute pancreatitis occurred in about 0.3 percent of people on the drug, a rate not statistically different from comparators. In STEP 1, there were 3 cases among more than 1,300 people on Wegovy and none among about 650 on placebo, too few events to draw a conclusion in either direction.

Large cardiovascular outcome trials and the 2022 meta-analysis of GLP-1 agonists likewise found no significant excess of pancreatitis. Some observational database studies have suggested a higher rate; others have not. Grading that evidence honestly: randomized data show no clear increase, observational data are mixed, and regulators keep the warning as a precaution. That is a very different picture from the gallbladder finding, where the signal is consistent.

What remains true is that pancreatitis, whatever its cause, is a medical emergency, and that gallstones, which the drug does raise, are themselves a leading cause of it. So the practical advice does not depend on resolving the debate.

The hallmark symptom is severe, persistent pain in the upper abdomen that often bores through to the back, worsens after eating, and may ease slightly when leaning forward. Vomiting that does not relieve the pain, a tender or swollen belly and fever complete the picture. This is not the mild, comes-and-goes discomfort of a slow stomach. The Mayo Clinic’s patient information is explicit that this pattern means stopping the drug is a clinician’s decision made urgently, not a patient’s decision made quietly at home.

Stomach paralysis, ileus and the slowed stomach: separating fact from headline

“Ozempic stomach paralysis” became a headline in 2023 after a small number of lawsuits and news features. The medical term is gastroparesis, a condition in which the stomach empties abnormally slowly without any physical blockage. The tricky part is that slowing the stomach is exactly what semaglutide is designed to do.

In nearly everyone, that slowing is modest and reversible; gastric emptying largely returns toward normal within weeks of stopping the drug. In a small number of people, mostly in post-marketing reports rather than trials, delayed emptying has been severe enough to cause persistent vomiting, bloating and inability to eat. People with diabetes are already at higher risk of gastroparesis because high blood sugar damages the nerves that coordinate stomach contractions, which makes it hard to know how much the drug contributed.

Ileus is a related but distinct problem: the intestine temporarily stops pushing contents along, causing bloating, no bowel movements, no passing of gas, and vomiting. In September 2023 the FDA added ileus to the Ozempic label based on post-marketing reports. The label language is careful: because these reports come from voluntary reporting in a population of unknown size, it is not possible to estimate how often ileus occurs or to prove the drug caused it. That is expert-opinion-level evidence, appropriately flagged, and a reason for vigilance rather than alarm.

The anesthesia question grew from the same mechanism. If the stomach still holds food during sedation, that food can be inhaled into the lungs. Case reports prompted anesthesiology groups in 2023 and 2024 to recommend that anyone on a GLP-1 medicine tell the surgical team beforehand so fasting or medication timing can be adjusted. That is a conversation to have with the surgeon and anesthesiologist, not a reason to alter the medicine on one’s own.

The distinction to hold onto: fullness that passes and nausea that eases over weeks is the mechanism. Vomiting that will not stop, a distended belly, and no bowel movements or gas for days is a stop-everything phone call.

Eyes and thyroid: the boxed warning and the newest signal

Every semaglutide package carries a boxed warning, the strongest warning US regulators issue, about thyroid C-cell tumors. It is worth reading exactly what it says, because it is widely misunderstood.

In rats and mice, semaglutide caused tumors of the thyroid’s calcitonin-producing C cells at doses relevant to human exposure. Rodent C cells are unusually sensitive to GLP-1, and whether the finding applies to people is unknown. Human trials and years of post-marketing surveillance have not shown a clear increase in medullary thyroid cancer, although this cancer is so rare that a small effect would be hard to detect. Because of that uncertainty, the drug is not prescribed to anyone with a personal or family history of medullary thyroid carcinoma or of MEN 2, a genetic syndrome that raises the risk of it. The symptom to report is a lump or swelling in the neck, hoarseness that persists, or trouble swallowing.

Diabetic retinopathy is the second eye-adjacent concern, and it has randomized-trial support. In the SUSTAIN 6 cardiovascular trial, retinopathy complications occurred in 3.0 percent of people on Ozempic versus 1.8 percent on placebo. The prevailing explanation is that a rapid improvement in blood sugar, from any therapy including insulin, can temporarily worsen existing retinopathy. People with known retinopathy are advised to keep their eye exams on schedule while starting the drug.

NAION is the newest and most discussed. A 2024 Harvard-affiliated observational study reported a several-fold higher rate of this optic nerve stroke in semaglutide users, and Danish registry data suggested roughly a doubling of a very low baseline risk. Observational studies cannot prove causation, and the affected people tend to share risk factors such as diabetes, sleep apnea and vascular disease. Still, the European regulator judged the pattern strong enough to list NAION as a very rare side effect in 2025. Its calling card is sudden, painless loss of vision or a dark curtain in one eye, usually noticed on waking. That is an emergency eye evaluation the same day, whatever the cause turns out to be.

Low blood sugar, dehydration and the kidneys

Semaglutide alone rarely causes hypoglycemia, or dangerously low blood sugar, because it only prompts insulin release when glucose is high. The risk changes when it is combined with insulin or a sulfonylurea, a class of older diabetes tablets that push insulin out regardless of glucose level. In trials that pairing raised hypoglycemia rates meaningfully, which is why clinicians often adjust those other medicines when semaglutide is added. That adjustment is theirs to make; the reader’s job is to recognize the symptoms.

Hypoglycemia announces itself with shakiness, sweating, a racing heart, sudden hunger, confusion, irritability and, if it progresses, slurred speech or fainting. Anyone on a combination regimen should know their clinician’s specific plan for treating a low and for reporting recurring episodes.

Dehydration is the quieter risk and the one MedlinePlus singles out for kidney health. Vomiting and diarrhea lose fluid directly. A suppressed appetite often takes thirst down with it. The kidneys, which depend on steady blood flow, can be strained by that combination, and post-marketing reports include acute kidney injury, in some cases needing dialysis, mostly in people who were vomiting heavily or already had kidney disease. The signal came from case reports, not trials, and the mechanism is fluid loss rather than direct kidney toxicity. That is reassuring in one sense, because it is preventable, and sobering in another, because it is easy to slide into without noticing.

Warning signs of significant dehydration include dark urine or urinating far less than usual, dizziness on standing, a dry mouth that water does not fix, and a rapid heartbeat. Anyone who cannot keep fluids down for more than a day, or who notices swelling in the legs alongside reduced urination, needs a clinician’s assessment. It is one of the few side effects where the fix is straightforward and the cost of ignoring it is not.

Hair loss, muscle loss and the so-called Ozempic face

Some of the most searched semaglutide side effects are not really drug effects. They are weight-loss effects, and understanding the difference changes how to think about them.

Take hair. In STEP 1, hair loss was reported by 3 percent of people on Wegovy and 1 percent on placebo. The pattern fits telogen effluvium, a temporary shedding that follows any major physiological stress, including rapid weight loss, surgery, childbirth or a crash diet. Hair follicles shift into a resting phase and shed two to four months later, then regrow. Nothing in semaglutide’s mechanism targets hair, and the same shedding is seen after bariatric surgery. Adequate protein intake, which is harder when appetite is low, is the usual conversation.

“Ozempic face” is a phrase coined by a dermatologist and amplified by social media. It describes the hollowed cheeks and looser skin that can follow substantial fat loss, especially in people over 40 whose skin has less elastic recoil. Harvard Health’s discussion of GLP-1 side effects puts it bluntly: the face changes because facial fat is lost, and any method of losing that much weight would do the same. It is not a drug-specific toxicity.

Muscle deserves more attention than it gets. Whenever a person loses a lot of weight, some of it is lean tissue. Body-composition substudies from semaglutide trials found that roughly 25 to 40 percent of the weight lost was lean mass, a proportion similar to what is seen with diet-induced weight loss. That is not muscle being destroyed by the drug; it is the normal cost of eating far less, and it is why resistance exercise and protein are part of standard counseling alongside the prescription.

Fatigue and feeling cold fit the same category. Eating substantially fewer calories lowers energy availability and, for some people, body temperature regulation. These effects tend to settle as weight stabilizes. They are real, they affect quality of life, and they are worth raising at follow-up, but they belong on the ledger of weight loss rather than the ledger of pharmacology.

Mood, sleep and mental health: what regulators found

In mid-2023, European regulators opened a review after receiving reports of suicidal thoughts in people taking GLP-1 medicines. The question is serious, and the way it was answered is a good model for how side-effect signals should be handled.

Both the European Medicines Agency and the US FDA examined clinical trial data, post-marketing reports and large observational databases. In January 2024 the FDA published a preliminary evaluation stating that the evidence did not demonstrate a causal link between GLP-1 receptor agonists and suicidal thoughts or actions, while noting it could not definitively rule out a small risk and would keep monitoring. The EMA reached a similar conclusion in April 2024. Several large cohort studies since then have found no increased risk, and some have reported lower rates of depression diagnoses among users compared with people on other diabetes medicines, though that could reflect who is chosen for the drug rather than the drug itself.

The evidence grade, then: randomized trials show no signal, large observational studies are reassuring, and regulators consider the question open only at the margins. Because weight-management trials excluded people with recent serious mental illness, the picture in that group is less complete, which is one reason mental health history is part of the prescribing conversation.

What people do describe, in trials and clinics, is more ordinary. Appetite and pleasure from food are intertwined, and some people feel flat or joyless about eating in the early months. A minority report changes in alcohol interest, which researchers are now studying formally. Sleep can be disrupted by reflux or by lying down with a stomach that empties slowly.

Any new or worsening depressed mood, hopelessness, or thoughts of self-harm should be reported to a clinician promptly, regardless of what the population-level data show. Population data describe averages; a clinician is responsible for one person. The labeling for weight-management products advises exactly this kind of monitoring, and it is good practice with any medicine that changes appetite and reward.

What the evidence actually says about GLP-1 side effects: grading the strength

Not every side effect on the label carries the same weight of proof. Sorting them by the kind of evidence behind them is the single most useful thing a reader can do to calibrate worry.

Established by randomized trials. Nausea, vomiting, diarrhea, constipation, abdominal pain, reduced appetite, mild heart-rate increase, injection-site reactions and gallbladder disease all show clear, reproducible differences between drug and placebo across multiple trials involving tens of thousands of people. Worsening of pre-existing diabetic retinopathy has randomized support from SUSTAIN 6. Hair loss has trial data at the weight-management strength. Hypoglycemia when combined with insulin or sulfonylureas is well documented. These are the effects a person can reasonably expect might happen.

Supported by observational data, with regulators judging the signal real. NAION is the clearest example: several cohort and registry studies, a plausible mechanism through vascular changes, and a 2025 regulatory decision to list it as very rare. Observational studies cannot exclude the possibility that people prescribed semaglutide were already more prone to the condition, which is why the risk is described as very rare and possible rather than proven and common.

Post-marketing reports and expert caution. Ileus, severe gastroparesis, acute kidney injury from dehydration, and aspiration during anesthesia rest on case reports and pharmacovigilance databases. These cannot estimate frequency and cannot prove causation. Regulators list them so clinicians stay alert, not because they occur often.

Theoretical or unproven. Thyroid C-cell tumors come from rodent studies with no confirmed human equivalent. Pancreatitis has a label warning grounded in early case reports and biological plausibility, but pooled randomized data show no significant increase. Suicidality was reviewed and, on current evidence, not linked.

Two caveats apply across all tiers. Trials excluded people with significant kidney, liver, or psychiatric disease and rarely enrolled adults over 75, so real-world populations may differ. And the longest randomized follow-up is roughly four years, which is short for a medicine some people may take for decades. Long-term surveillance is ongoing, and honest counseling says so.

Common myths about Ozempic side effects, corrected

Viral claims tend to take a true fragment and stretch it. Here are the ones that circulate most, alongside what the evidence supports.

Myth: Ozempic paralyzes the stomach in most people. Semaglutide slows stomach emptying in everyone, by design and reversibly. Severe, persistent gastroparesis is a rare post-marketing report, not a common outcome, and it overlaps with diabetes-related nerve damage that predates the drug.

Myth: It causes thyroid cancer. The boxed warning reflects rodent studies. Human data have not shown a clear increase in medullary thyroid cancer, though surveillance continues, and the drug is avoided in people with a personal or family history of that specific cancer.

Myth: Pancreatitis is common. Confirmed pancreatitis occurred in well under 1 percent of trial participants and at rates similar to comparators. It remains a listed warning because the consequences are severe, not because it is frequent.

Myth: The drug melts your face. Facial hollowing follows large fat loss from any cause. It is a feature of weight loss, not a toxic effect of semaglutide on skin.

Myth: Nausea means it is not working, or it means it is working. Neither. Weight loss and glucose control in trials were similar between people who felt nauseated and people who did not. Nausea is a side effect, not a progress indicator.

Myth: If side effects appear, stop the medicine and restart later. Stopping and restarting on one’s own can reset the body’s adjustment period and complicate diabetes control. Timing changes belong to the prescriber, who may adjust the escalation pace instead.

Myth: Compounded semaglutide has the same side-effect profile. The trial data describe the approved products. Compounded versions are not FDA-approved, are not tested for safety or effectiveness, and have been linked to dosing errors. Their side-effect profile is, by definition, unknown.

Myth: It causes depression and suicidal thoughts. Regulators in the US and Europe reviewed this question in 2023 and 2024 and found no causal link on the available evidence, while continuing to monitor.

The pattern in every case is the same: a real mechanism or a real rare event, inflated into a common one. Precise numbers are the antidote.

Living with the common side effects: what actually helps, according to clinics

Most people who get through the first two or three months on semaglutide describe the same arc: rough patches around each dose increase, then a settling. The suggestions that clinics give for those patches are unglamorous, low-risk and grounded in the drug’s mechanism.

Meal size matters more than meal content. A stomach that empties slowly copes better with a small plate than a large one, so five modest meals often beat three big ones. Stopping when comfortably full, rather than clearing the plate, is easier when the drug is doing its job and harder when old habits run the show.

Fat and fried foods slow emptying further and are the most reliable nausea triggers reported by patients; the Mayo Clinic and Cleveland Clinic both list greasy, heavy meals as things to limit early on. Very sweet foods and carbonated drinks come up nearly as often. Bland, lower-fat choices in the first days after an injection tend to sit better.

Fluids are non-negotiable, for the kidney reasons already covered. Sipping through the day works better than large gulps, which can trigger fullness and nausea in a stomach that is already slow.

Constipation responds to the same measures it always has: fiber from vegetables, fruit and whole grains, plenty of water, and daily movement. Because fiber without fluid can worsen bloating, the two go together. If constipation lasts more than a few days despite these changes, that is a conversation for the prescriber rather than a reason to experiment with products on one’s own.

Timing the injection is a small lever some clinicians discuss. People who feel worst in the 24 to 48 hours after a dose sometimes prefer injecting before a quiet stretch. Any change in timing is worth agreeing with the prescriber first, because the once-weekly rhythm matters for steady drug levels.

Finally, keeping a simple log of symptoms, their timing relative to the injection and what was eaten gives the clinician real information at follow-up. A slower dose escalation is the most evidence-supported way to reduce GI effects, and a good log is what makes that decision an informed one rather than a guess.

When to see a doctor about Ozempic side effects

Most side effects of semaglutide are uncomfortable rather than dangerous, and the distinction is usually clear once you know what to look for. Every decision about pausing, adjusting or stopping the medicine belongs to the prescribing clinician, but recognizing the following signs early is the patient’s part of the partnership.

Seek emergency care immediately for:

• Severe, persistent pain in the upper abdomen, especially if it spreads to the back and comes with vomiting; this is the pattern of pancreatitis.
• Sudden loss of vision, blurring, or a dark shadow in one eye, which requires same-day eye evaluation.
• Signs of a serious allergic reaction: swelling of the face, lips, tongue or throat, difficulty breathing, or widespread hives.
• Severe hypoglycemia with confusion, inability to swallow safely, seizure or loss of consciousness, particularly in people also taking insulin or a sulfonylurea.
• A swollen, hard belly with no bowel movements or gas for days, plus vomiting, which may indicate ileus or a blockage.

Contact your prescribing clinician the same day for:

• Steady pain in the upper right abdomen, fever, yellowing of the skin or eyes, or pale stools, suggesting gallbladder disease.
• Vomiting or diarrhea lasting more than a day, or any inability to keep fluids down, because of the kidney risk from dehydration.
• Very dark urine, urinating much less than usual, or dizziness on standing.
• A lump or swelling in the neck, persistent hoarseness or difficulty swallowing.
• New or worsening low mood, hopelessness or thoughts of self-harm.
• Any new vision change in someone with known diabetic retinopathy.

Raise at your next scheduled visit:

• Nausea, reflux or constipation that is manageable but not improving after several weeks at the same dose.
• Hair shedding, fatigue, feeling cold, or concern about muscle loss.
• Any planned surgery or procedure requiring sedation, so the team can plan around delayed stomach emptying.
• Any new medicine, including over-the-counter products or supplements, since a slower stomach can change how other drugs are absorbed.

One more rule that clinicians repeat: never stop semaglutide abruptly without telling the prescriber, especially if it is managing diabetes or heart or kidney risk. The medicine is one part of a plan, and the plan is what protects you.

Compounded semaglutide and research peptides: why the side-effect data do not transfer

Everything in this article describes Ozempic and Wegovy as approved and tested. A parallel market of compounded semaglutide, and of vials sold online as “research peptides,” grew during the shortage years, and it deserves a plain statement of status.

Compounded drugs are made by pharmacies for individual patients when an approved product is unavailable or unsuitable. Under US law, compounding of a drug that is essentially a copy of an approved product is permitted mainly during a declared shortage. The FDA declared the semaglutide shortage resolved in February 2025, after which that allowance narrowed sharply. Compounded products are not FDA-approved, are not reviewed for safety, effectiveness or quality before sale, and the agency has received reports of adverse events, including hospitalizations, tied to dosing errors when people measured doses from multi-use vials or misread units.

“Research peptides” labeled “not for human consumption” occupy a different and starker category. They are not medicines. They have no verified identity, purity or sterility, and they are not for sale for human use or for self-injection. Any side-effect information here simply does not apply to them, because there is no way to know what is in the vial.

Why does this matter for a side-effect discussion? Because the reassuring trial numbers, the 3 to 4 percent discontinuation rate, the known frequency of gallbladder events, the clean pancreatitis data, all describe a specific, verified molecule at specific, verified strengths, given under medical supervision with laboratory monitoring. Change any of those variables and the numbers no longer hold.

The same logic applies to using approved semaglutide outside its labeled purposes, for instance for weight loss in someone without obesity or overweight, or for conditions still under study such as alcohol use disorder or Alzheimer’s disease. Evidence for some of those uses is emerging from trials; for others it is preliminary. Whether any of it justifies a prescription for a particular person is a decision for the treating clinician, weighing that person’s history against evidence that, for now, ranges from strong to speculative.

The medicine itself has been studied in more than 100,000 trial participants. That is precisely why the version that comes with a prescription, a pharmacist and follow-up appointments is the only version whose risks anyone can honestly describe.

Frequently asked questions

How long do Ozempic side effects last?

For most people, digestive side effects are strongest in the first few weeks and after each dose increase, then ease over one to two months as the stomach adapts. In trials, nausea rates fell steadily after the escalation period even though drug levels stayed constant. Symptoms that persist unchanged for months, or that worsen rather than improve, should be discussed with the prescribing clinician, who may slow the pace of dose changes.

Are semaglutide side effects different between Ozempic and Wegovy?

The side effects are the same in kind because both contain semaglutide, but they are more frequent with Wegovy, which is dosed higher for weight management. In the STEP 1 trial, 44 percent of Wegovy users reported nausea compared with 16 to 20 percent in Ozempic diabetes trials. Gallbladder events and hair loss were also more common at weight-management strengths. Discontinuation rates for digestive reasons stayed under 5 percent in both.

Does Ozempic cause gallbladder problems?

Yes, the link is established by randomized trials. A 2022 meta-analysis of 76 trials found GLP-1 medicines increased gallbladder or biliary disease risk by about 37 percent relative to comparators, roughly 27 extra events per 10,000 person-years. Rapid weight loss and reduced gallbladder contraction both contribute. Steady pain under the right ribs, fever, or yellowing skin after starting the medicine warrants same-day medical attention.

What are the signs of Ozempic pancreatitis?

The hallmark is severe, persistent pain in the upper abdomen that often radiates to the back, worsens after eating, and comes with vomiting that does not relieve it, sometimes with fever and a tender belly. This is an emergency requiring immediate care. Trials found confirmed pancreatitis in fewer than 1 percent of participants at rates similar to comparators, so it is rare, but the label carries a warning because the condition itself is serious.

Can Ozempic cause stomach paralysis?

Semaglutide slows stomach emptying in everyone, which is part of how it works and is reversible after stopping. Severe, persistent gastroparesis has been described in post-marketing reports, but it is rare and hard to separate from diabetes-related nerve damage that can cause the same problem. Vomiting that will not stop, a distended abdomen, or no bowel movements or gas for days should prompt an urgent call to the prescriber.

What are the most common GLP-1 side effects overall?

Across the GLP-1 class, the common side effects are nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite and belching, plus mild injection-site reactions and a small rise in resting heart rate. These stem directly from the drugs’ effects on stomach emptying and appetite. Rarer effects shared across the class include gallbladder disease, dehydration-related kidney strain, and worsening of existing diabetic retinopathy during rapid blood sugar improvement.

Does Ozempic affect your eyes?

Two eye concerns are documented. People with existing diabetic retinopathy had more complications in one trial, likely because fast blood sugar improvement can temporarily worsen it, so eye exams should stay on schedule. Separately, observational studies linked semaglutide to NAION, a sudden optic nerve stroke, and European regulators listed it as very rare in 2025. Sudden painless vision loss or a dark curtain in one eye needs same-day eye evaluation.

Are Wegovy side effects worse for people without diabetes?

Not because of diabetes status itself, but because Wegovy is prescribed at higher strengths than Ozempic, side effects are more frequent. People without diabetes also have a very low risk of hypoglycemia on semaglutide alone. The gallbladder risk appears somewhat higher when the drug is used for weight loss, probably because weight loss is larger and faster. Individual tolerance varies widely, and slower dose escalation is the main tool clinicians use.

Does Ozempic cause hair loss?

Hair shedding was reported by 3 percent of people on Wegovy versus 1 percent on placebo in the STEP 1 trial. The pattern matches telogen effluvium, a temporary shedding two to four months after any major physical stress, including rapid weight loss from diet or surgery. It typically regrows as weight stabilizes. Nothing in semaglutide’s mechanism targets hair follicles, so this is best understood as a weight-loss effect rather than a drug toxicity.

Is it safe to have surgery while taking Ozempic?

It can be, with planning. Because semaglutide slows stomach emptying, food may remain in the stomach after standard fasting, and rare cases of aspiration during sedation have been reported. Anesthesiology groups advise telling the surgical team about any GLP-1 medicine well before the procedure so they can adjust fasting or medication timing. That decision rests with the surgeon, anesthesiologist and prescribing clinician together, not with the patient alone.

References

• Semaglutide Injection – MedlinePlus Drug Information
• GLP-1 Agonists – Cleveland Clinic

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.